Core Insights - Entera Bio Ltd. reported financial results and business updates for Q1 2025, highlighting progress in its oral peptide and protein replacement therapies, particularly EB613 for osteoporosis and Oral OPK-88006 for metabolic diseases [1][2][12]. Financial Performance - As of March 31, 2025, Entera had cash and cash equivalents of $20.6 million, with $8 million allocated for collaboration with OPKO, expected to sustain operations through mid-Q3 2026 [12]. - The net loss for Q1 2025 was $2.6 million, or $0.06 per share, compared to a net loss of $2.0 million, or $0.05 per share, in Q1 2024 [13][21]. Product Development - EB613 is the first oral anabolic treatment for postmenopausal women with osteoporosis, with plans to initiate a Phase 1 study in H2 2025 [2][3]. - The company is preparing for a pivotal program for EB613, which has shown promising results in increasing bone mineral density (BMD) [3][4]. - Entera is also developing Oral OPK-88006, a dual-acting GLP1/Glucagon tablet for metabolic diseases, with a 40% stake in its economics [2][10]. Clinical Advancements - EB613's early mechanistic effects were selected for oral presentation at the 2025 World Congress on Osteoporosis, indicating strong interest in its clinical potential [2]. - The SABRE initiative is advocating for regulatory reform to qualify BMD as a surrogate endpoint for fracture risk, which could facilitate the approval of new osteoporosis treatments [3]. Team Expansion - Entera has strengthened its core team with the appointment of Leslie Gautam as Chief Business Officer and Cherin Smith as Head of Clinical Operations, both bringing extensive experience in women's health and clinical operations [8][11].

Core Insights - Entera Bio Ltd. announced positive results from a Phase 2 study of EB613, an oral PTH(1-34) tablet aimed at treating postmenopausal women with osteoporosis at high risk for fractures [1][2][4] - The study demonstrated significant increases in bone mineral density (BMD) across various skeletal sites compared to placebo, indicating the potential for rapid bone strengthening and fracture resistance [2][3] Company Overview - Entera Bio is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [5] - The company's lead product, EB613, is positioned as the first oral anabolic treatment for postmenopausal women with low BMD and high-risk osteoporosis [5] - Entera is preparing to initiate a Phase 3 registrational study for EB613 following FDA qualification of a quantitative BMD endpoint [5] Study Details - The Phase 2 study involved 161 postmenopausal women and assessed the effects of EB613 over 6 months, showing improvements in integral volumetric BMD, trabecular volumetric BMD, cortical thickness, and cortical surface BMD compared to placebo [2][3] - 3D-DXA analysis indicated a dual effect of EB613, stimulating bone formation while inhibiting resorption, with significant improvements noted in both trabecular and cortical bone [1][2] Market Context - Osteoporosis is a significant health concern, affecting approximately 200 million women globally, with a high risk of fragility fractures [4] - Current injectable anabolic treatments are not viable for many patients, highlighting the need for an effective oral treatment option like EB613 [4]

Core Insights - Entera Bio Ltd. is developing EB613, the first once-daily oral anabolic PTH(1-34) tablet for postmenopausal women with osteoporosis at high risk for fracture [1][4] - The Phase 2 study showed significant increases in bone mineral density (BMD) at various skeletal sites compared to placebo, indicating a dual effect of stimulating bone formation and inhibiting resorption [1][2] - The company plans to initiate a Phase 3 registrational study for EB613 following positive Phase 2 results [5] Company Overview - Entera Bio is a clinical-stage company focused on oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology [5] - The company's pipeline includes five differentiated oral peptide programs targeting conditions such as osteoporosis, hypoparathyroidism, and obesity [5] - EB613 is positioned as a solution for the treatment gap in osteoporosis care, aiming to provide a simple daily tablet for patients who currently lack effective treatment options [4][5] Clinical Study Findings - The Phase 2 study randomized 161 postmenopausal women and demonstrated early effects on trabecular and cortical bone, suggesting rapid bone strengthening and fracture resistance [2][3] - 3D-DXA analysis revealed substantial improvements in areal BMD at the total hip and femoral neck, consistent with results from subcutaneous teriparatide [3] - The study's findings indicate a broad distribution of bone loss with placebo and a similar distribution of bone gain with EB613 in the femur [2] Market Context - Osteoporosis affects approximately 200 million women globally, with a significant risk of fragility fractures, particularly in postmenopausal women [4] - Current injectable anabolic treatments are not viable for many patients, highlighting the need for an effective oral treatment like EB613 [4]

Financial Performance - Entera Bio Ltd. reported revenues of $181,000 for the year ended December 31, 2024, compared to no revenues in 2023[500]. - The company incurred a net loss of $9,541,000 in 2024, an increase from a net loss of $8,889,000 in 2023, reflecting a 7.3% increase in losses year-over-year[500]. - Total operating expenses for 2024 were $9,594,000, up from $8,891,000 in 2023, indicating an increase of approximately 7.9%[500]. - The net loss for the year ended December 31, 2024, was $9,541,000, compared to a net loss of $8,889,000 in 2023, representing an increase of approximately 7.3%[508]. - The company reported a total loss before taxes of $9,527 for the year ended December 31, 2024, compared to $8,860 in 2023[625]. Cash and Assets - Cash and cash equivalents decreased to $8,660,000 as of December 31, 2024, down from $11,019,000 in 2023, representing a decline of 21.4%[497]. - The total assets of Entera Bio Ltd. decreased to $9,390,000 in 2024 from $11,765,000 in 2023, a reduction of 20.2%[497]. - The company’s accumulated deficit increased to $113,927,000 in 2024 from $104,386,000 in 2023, reflecting a rise of 9.8%[497]. - Cash flows used in operating activities decreased to $6,818,000 in 2024 from $7,310,000 in 2023, indicating improved cash management[508]. - The company expects its available funds to support operations into the third quarter of 2026, excluding the initiation of the Phase 3 study for EB613[513]. Shareholder Equity and Capital Raising - The number of shares outstanding increased to 38,837,220 as of December 31, 2024, from 35,476,341 in 2023, marking an increase of 6.7%[497]. - The company raised $3,960,000 through ATM programs in 2024, a significant increase from $5,000 in 2023, indicating enhanced financing activities[508]. - An aggregate of 2,236,126 ordinary shares were issued under the Leerink ATM Program for net proceeds of $3,840 at a weighted average price of $1.77 per share during the year ended December 31, 2024[589]. - The Company raised approximately $6.6 million from a private offering (2023 PIPE) by issuing 6,662,389 ordinary shares at a purchase price of $0.835 per unit[592]. - The Company issued 143,049 ordinary shares to non-executive board members in lieu of cash board fees, valued at $263 based on the market price at the grant date[600]. Operational Developments - The company is preparing to initiate a Phase 3 registrational study for its product candidate EB613, which is aimed at treating post-menopausal women with low bone mineral density[511]. - The ongoing conflict in Israel has had an immaterial impact on the company's operations and financial condition during 2024 and 2023[515]. - The Company entered into a collaboration agreement with OPKO, granting an exclusive license for developing a GLP-1/glucagon dual agonist, with a revenue sharing of 40% for Entera Bio and 60% for OPKO[637]. - The Company has entered into a research collaboration agreement with OPKO Biologics, Inc., recognizing total expenses of $71 for the year ended December 31, 2024[580]. Compensation and Expenses - The company incurred share-based compensation expenses of $2,556,000 in 2024, up from $1,689,000 in 2023, reflecting increased employee compensation costs[508]. - The Company has not paid any cash dividends and does not anticipate doing so in the foreseeable future[549]. - The Company incurred transaction costs of approximately $1,000 related to the issuance of Broker Warrants and Finder Warrants[599]. Lease and Tax Information - The Company has a total lease liability of $272 as of December 31, 2024, with future minimum lease payments totaling $301[574]. - As of December 31, 2024, the deferred tax assets were $20,873, with a valuation allowance of the same amount, indicating uncertainty in realization[630]. - The Company has a weighted-average remaining lease term of 1.54 years and a weighted-average discount rate of 14% for its operating leases as of December 31, 2024[573]. Stock Options and Warrants - As of December 31, 2024, Entera Bio Ltd. had a total of 7,652,654 outstanding options with a weighted average exercise price of $2.32, compared to 7,105,414 options at $2.57 in 2023[615]. - The aggregate intrinsic value of outstanding options as of December 31, 2024, was $3,632, while the intrinsic value of exercisable options was $2,255[615]. - The company granted 2,116,331 options in 2024 at an average exercise price of $1.49, compared to 1,798,884 options at $0.78 in 2023[615]. - The exercise price for Investor Warrants is set at $1.00 per share, which are immediately exercisable and expire five years from the date of issuance[594].

Exhibit 99.1 JERUSALEM, March 28 2025 –Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. "2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1- 34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balan ...

Core Insights - Entera Bio Ltd. reported significant advancements in its oral peptide and protein replacement therapies, particularly in osteoporosis and obesity treatments, during 2024 [2][4][12] - The company aims to address unmet medical needs with its innovative N-Tab™ platform, focusing on oral formulations for conditions like osteoporosis, hypoparathyroidism, and short bowel syndrome [12] Financial Performance - For the year ended December 31, 2024, Entera reported a net loss of $9.5 million, or $0.25 per share, compared to a net loss of $8.9 million, or $0.31 per share, for 2023 [11][21] - As of December 31, 2024, the company had cash and cash equivalents of $8.7 million, which increased to $21 million by March 28, 2025, due to investments from institutional shareholders [9] Key Achievements - Entera advanced its EB613 program, the first oral PTH(1-34) tablet treatment candidate for women with osteoporosis, and is preparing for a pivotal Phase 3 study [3][4] - The company also announced the first GLP-1/glucagon agonist peptide tablet candidate for obesity, with promising pharmacokinetic results [5][10] - Entera's collaboration with OPKO Health has been pivotal in developing its oral peptide therapies, including the oral GLP-2 tablets for short bowel syndrome [10][12] Research and Development - Research and development expenses for 2024 were $4.5 million, consistent with the previous year, reflecting ongoing efforts in clinical trials and preparation for future studies [9][21] - The company is focused on innovative approaches to osteoporosis treatment, with the SABRE project under FDA review to qualify bone mineral density as a surrogate endpoint for fractures [3][6] Market Potential - Entera targets a significant market with an estimated 200 million women suffering from osteoporosis, highlighting the need for new treatment options [3] - The company's oral therapies aim to improve patient compliance and address the limitations of current injectable treatments for conditions like short bowel syndrome and obesity [10][12]

Core Viewpoint - OPKO Health and Entera Bio have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for treating obesity and metabolic disorders, with plans to file an Investigational New Drug application with the FDA later this year [1][2]. Group 1: Collaboration Details - OPKO will hold a 60% ownership interest in the program, while Entera will hold 40%, and they will share development costs accordingly [2]. - OPKO purchased 3,685,226 ordinary shares of Entera at $2.17 per share to fund Entera's share of costs through Phase 1 of the development program [2]. - Entera has the option to continue funding its share post-Phase 1 to maintain its ownership interest; if it opts out, it will retain a 15% interest in the program [2]. Group 2: Product Information - The program combines OPKO's long-acting oxyntomodulin analog (OPK-88006) with Entera's N-Tab™ technology, which has shown favorable pharmacodynamic and pharmacokinetic data [1][5]. - Oxyntomodulin is a naturally occurring peptide hormone that suppresses appetite and induces weight loss, with additional cardioprotective and anti-fibrotic properties [5]. Group 3: Company Backgrounds - Entera Bio focuses on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology, with a pipeline that includes five oral peptide programs [6]. - OPKO Health is a multinational biopharmaceutical and diagnostics company aiming to establish leading positions in rapidly growing markets through its discovery and commercialization expertise [7].

Company Overview - Entera Bio Ltd. is a clinical stage company focused on developing oral peptide and protein replacement therapies in tablet form, addressing significant unmet medical needs [2] - The company utilizes a proprietary technology platform known as N-Tab™ and has a pipeline that includes five differentiated, first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2 [2] Product Development - The most advanced product candidate, EB613, is being developed as the first oral osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low bone mineral density (BMD) and high-risk osteoporosis [2] - A Phase 2 study of EB613 tablets (n=161) met primary and secondary endpoints related to bone turnover biomarkers and BMD [2] - Entera is preparing to initiate a Phase 3 registrational study for EB613 following FDA's qualification of a quantitative BMD endpoint [2] - The EB612 program is aimed at developing the first oral PTH(1-34) tablet for hypoparathyroidism [2] - The company is also developing the first oral oxyntomodulin for obesity treatment and the first oral GLP-2 peptide tablet for rare malabsorption conditions in collaboration with OPKO Health [2] Upcoming Conferences - Entera Bio will participate in several upcoming conferences, including: - Leerink Partners Global Healthcare Conference on March 12, 2025, in Miami, FL [2] - 2025 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases with an oral presentation on April 11, 2025, and a poster presentation on April 13, 2025, in Rome [2] - 2025 BIO International Convention from June 16-19, 2025, in Boston, MA [2]

Core Viewpoint - Entera Bio Ltd. is advancing its oral peptide therapy EB613 for osteoporosis, with two abstracts accepted for presentation at the upcoming WCO-IOF-ESCEO congress in April 2025, highlighting the company's commitment to addressing significant health concerns in osteoporosis treatment [1][4]. Group 1: Product Development - EB613 is being developed as the first once-daily oral anabolic PTH(1-34) tablet treatment aimed at high-risk post-menopausal women with osteoporosis [2][6]. - A Phase 2 study of EB613 showed a fast onset of action and significant increases in bone mineral density (BMD) across all skeletal sites, along with increased bone formation and reduced bone resorption [2][6]. - The company plans to initiate a Phase 3 registrational study for EB613 following FDA qualification of a quantitative BMD endpoint [7]. Group 2: Market Need and Impact - Osteoporosis poses a serious health risk, with an estimated 200 million women affected globally, and 50% of women and 20% of men over 50 at risk of fragility fractures [5]. - EB613 aims to provide a simple oral treatment option to address the treatment gap in current osteoporosis care, which often relies on injectable therapies [6]. Group 3: Presentation Details - The presentation titled "Effects of EB613 Tablets [Oral PTH(1-34)] on Trabecular and Cortical Bone Using 3D-DXA: Post-Hoc Results from Phase 2 Study" will be delivered as an oral presentation on April 11, 2025 [3]. - Another presentation, "EB613 Tablet Treatment [Oral PTH(1-34)] – Does PK Drive Bone Modeling Versus Bone Remodeling?" will be showcased as a poster from April 11 to April 13, 2025 [3].

Core Insights - Entera Bio Ltd. is advancing EB613, an oral anabolic PTH(1-34) tablet treatment aimed at high-risk post-menopausal women with osteoporosis, with abstracts accepted for presentation at the WCO-IOF-ESCEO congress in April 2025 [1][2][4] Company Overview - Entera Bio is a clinical-stage company focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab™ technology platform [7] - The company's pipeline includes five first-in-class oral peptide programs targeting PTH(1-34), GLP-1, and GLP-2, with EB613 being the most advanced candidate [7] Product Development - EB613 is designed to provide an anabolic boost to strengthen skeletal microarchitecture and induce rapid bone mineral density (BMD) gains, followed by consolidation with an antiresorptive agent [6] - A placebo-controlled Phase 2 study of EB613 demonstrated significant increases in BMD at all skeletal sites and improvements in bone formation and resorption markers [2][6] Market Need - Osteoporosis is a significant health concern, affecting approximately 200 million women globally, with a high risk of fragility fractures among individuals over 50 [5] - Current injectable anabolic treatments are not viable for most patients, highlighting the need for a simple oral treatment like EB613 [6] Upcoming Presentations - Two abstracts related to EB613 will be presented at the WCO-IOF-ESCEO congress, including an oral presentation on the effects of EB613 on trabecular and cortical bone and a poster presentation on pharmacokinetics [3]